Showing results (411-420 of 419) with videos related to
Sort By:
Pageof 42
You have reached the last page of results.This site can display upto 419 results.
Arthritis and Rheumatism|September 28, 2010
The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological reportTuhina Neogi, Daniel Aletaha, Alan J Silman, et al.Annals of the Rheumatic Diseases|March 18, 2024
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 updateLaure Gossec, Andreas Kerschbaumer, Ricardo J O Ferreira, et al.Annals of the Rheumatic Diseases|May 14, 2015
Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task forceJosef S Smolen, Ferdinand C Breedveld, Gerd R Burmester, et al.Clinical and Experimental Rheumatology|March 14, 2023
ERN ReCONNET points to consider for treating patients living with autoimmune rheumatic diseases with antiviral therapies and anti-SARS-CoV-2 antibody productsRosaria Talarico, Giuseppe Alvise Ramirez, Sofia C Barreira, et al.Annals of the Rheumatic Diseases|March 13, 2026
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 updateJosef S Smolen, Christopher J Edwards, Victoria Konzett, et al.Annals of the Rheumatic Diseases|January 24, 2020
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 updateJosef S Smolen, Robert B M Landewé, Johannes W J Bijlsma, et al.Nature Reviews. Rheumatology|January 7, 2021
The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNETRosaria Talarico, Silvia Aguilera, Tobias Alexander, et al.Annals of the Rheumatic Diseases|November 10, 2022
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 updateJosef S Smolen, Robert B M Landewé, Sytske Anne Bergstra, et al.Clinical and Experimental Rheumatology|March 29, 2022
The added value of a European Reference Network on rare and complex connective tissue and musculoskeletal diseases: insights after the first 5 years of the ERN ReCONNETRosaria Talarico, Silvia Aguilera, Tobias Alexander, et al.Pageof 42